clinical trial · NCT06555796
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
Amgen·phase1·active not recruiting·n = 50
Prostate CancerHigh-risk Biochemical RecurrenceHigh Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate CancerNon-metastatic Castration-sensitive Prostate CancerXaluritamig
brief summary
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
started
Sep 23, 2024
primary completion
Oct 8, 2026
completion
Dec 2, 2028
last updated
Jan 26, 2026
official title
A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol